Alternative proteins can help prevent the next pandemic
Animal agriculture is a chief contributor to antibiotic resistance and the spread of zoonotic disease. Meeting rising demand for meat by making it from plants or cultivating it from animal cells reduces the risk of superbugs and pandemics. Policymakers dedicated to improving public health outcomes should fund alternative protein research and support private sector incentives.
Save this document
Alternative proteins combat the threat of antibiotic resistance
Alternative proteins do not require antibiotics for their production and therefore will not contribute to the proliferation of antibiotic-resistant microorganisms. This is critically important to public health. In the United States, more than 70 percent of medically important antibiotics needed to treat humans are used in intensive meat production to foster animal growth and prevent illness.1 This widespread misuse promotes the development of antibiotic-resistant superbugs which spread easily from farms to people. According to the CDC’s 2019 Antibiotic Resistance Threats Report, “more than 2.8 million antimicrobial- resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. When Clostridioides difficile—a bacterium that is not typically resistant but can cause deadly diarrhea and is associated with antibiotic use—is added to these, the U.S. toll of all the threats in the report exceeds 3 million infections and 48,000 deaths.”2 A review by the U.K. government found that antimicrobial resistance is a more certain risk to humanity than climate change.3,4
Alternative protein production does not require antibiotics. This may be obvious for plant-based meat, as antibiotics are not used to produce any of the ingredients. The same is true for meat cultivated from cells. To avoid costly losses in product and production time, animal cell manufacturing industries use sterile equipment and inputs, as well as extensive monitoring and control systems, to grow animal cells without antibiotics. Absent from feedlots and slaughterhouses, these safeguards will allow the cultivated meat industry to provide clean, safe products without requiring antibiotic use.
Alternative proteins reduce the risk of new diseases and future pandemics
According to the United Nations Environment Programme, two of the seven most likely causes of the next pandemic are increasing demand for animal protein and unsustainable agricultural intensification: “Increasing demand for animal-source foods stimulates the intensification and industrialization of animal production… Since 1940, agricultural intensification measures such as dams, irrigation projects and factory farms have been associated with more than 25 per cent of all—and more than 50 per cent of zoonotic—infectious diseases that have emerged in humans.”6
Plant-based and cultivated meats are insusceptible to animal diseases and do not contribute to pandemic risk because they do not require the use of live animals. By advancing the industry for alternative proteins, we can reduce the risk of new diseases and pandemics resulting from animal agriculture.
Alternative proteins are a key tool to improve public health
Antibiotic resistance and pandemic risk are global scourges that can be extremely costly to taxpayers and governments, and they most adversely impact the people who are least able to adapt to these new realities, both in the United States and around the world.
The end of modern medicine through antibiotic resistance would most harm those who don’t have effective healthcare. Similarly, Covid-19 sent more than 100 million of the world’s most vulnerable people into extreme poverty, and as pandemics go, it was neither especially deadly nor especially transmissible. Another pandemic could be much worse.
U.S. public health and global health nonprofits should use their platforms to amplify the call for policy initiatives that prioritize alternative proteins. Much as governments do now in the realm of drug development, policymakers should prioritize public funding for alternative protein research and development, as well as incentivize private sector R&D and private sector manufacturing.
Blog
Cultivating a future where antibiotics still work
Learn why GFI expects the future of cultivated meat to be largely antibiotic-free, and what that means for global health.
References
- Ritchie, H. (2017). How Do We Reduce Antibiotic Resistance from Livestock? Our World in Data. (https://ourworldindata.org/antibiotic-resistance-from-livestock#licence).
- Centers for Disease Control and Prevention. (2019). 2019 AR Threats Report. (https://www.cdc.gov/drugresistance/biggest-threats.html)
- Roland, D. (2014, Dec. 11). How superbugs could cost the world $100 trillion by 2050. The Telegraph. (https://www.telegraph.co.uk/finance/economics/11285822/How-superbugs-could-cost-the-world-100-trillion-by-2050.html)
- O’Neill, J. (2014). Antimicrobial resistance: Tackling a crisis for the health and wealth of nations. (https://amr-review.org/sites/default/files/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf).
- Washington Post. (2012, Jul. 10). Resistance to antibiotics is becoming a crisis. (https://www.washingtonpost.com/opinions/resistance-to-antibiotics-is-becoming-a-crisis/2012/07/10/gJQAFwFfbW_story.html).
Related resources
Plant-based meat nutrition facts
Plant-based meats are more nutritious than conventional meat. Learn more about the nutrition facts by brand and the latest scientific findings.
Climate solutions
Alternative proteins play an essential role in meeting global climate goals. Learn more about what you can do to help change how meat is made.
The State of Global Policy on Alternative Proteins
Our annual State of Global Policy Report tracks public investment in alternative proteins and showcases the actions governments took to position themselves as leaders in the field.
Alternative proteins for a sustainable, secure, and prosperous future
Alternative proteins create a path to a sustainable, secure, and prosperous future. Policymakers should prioritize investments to improve the quality, affordability, and accessibility of alternative proteins.